Anti-IL23 in inflammatory bowel disease patients with dermatological indication: The shared gastroenterological-dermatological clinic experience

Dig Liver Dis. 2024 Jan;56(1):220-222. doi: 10.1016/j.dld.2023.11.012. Epub 2023 Nov 27.
No abstract available

Publication types

  • Letter

MeSH terms

  • Humans
  • Inflammatory Bowel Diseases* / complications
  • Infliximab

Substances

  • Infliximab